From Sequence to Spatial Pharmacology: A Translational Evidence Framework for Peptide Systems in Pancreatic Ductal Adenocarcinoma

In pancreatic ductal adenocarcinoma (PDAC), the problem is access, not merely affinity. Yet recent reviews emphasize discovery platforms, theranostic probes or clinical translation; to our knowledge, none appraises, across peptide roles, what the evidence shows about access, exposure and benefit by disease stage, including negative randomized results. This structured critical review introduces a spatial-pharmacology framework that asks of every peptide what job it performs (drug, targeting or penetration ligand, trigger, antigen or reporter), where it must act, which clinical state can reveal benefit, and which unresolved experiment most threatens translation. By classifying evidence maturity (tiers T0–T5) separately from outcome direction and profiling five translational domains, it compares heterogeneous systems without pooling and prevents evidence transfer between roles. We searched PubMed/MEDLINE, ClinicalTrials.gov, publisher records and citation chains through 13 August 2026 and purposively charted decision-informative programs in a source-linked atlas. Three cross-system conclusions emerge. First, early human evidence differs in kind by role (for example, target access for reporters, immunogenicity for vaccines) and is not interchangeable, while many direct, stromal and immune-enabling peptides remain preclinical. Second, evidence maturity and benefit often diverge: randomized evidence is limited, partly conference- or developer-reported, and largely negative or non-confirmatory, whereas supportive signals come mostly from lower evidence tiers. Third, the decisive missing evidence is role-specific: site-of-action exposure for direct, stromal and penetration peptides, setting-appropriate endpoints for vaccines, and effect on clinical decisions for reporters. We propose six minimum development standards; the framework is a planning heuristic, not a validated predictor of benefit.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-11-16
DOI
https://doi.org/10.3390/ph19111820
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From Sequence to Spatial Pharmacology: A Translational Evidence Framework for Peptide Systems in Pancreatic Ductal Adenocarcinoma

Ahmet Akif Kızılkurtlu, Fatih Çiftçi, Özgür Yılmaz
3 links
Pharmaceuticals
Pancreatic and Hepatic Oncology Research
article

From Sequence to Spatial Pharmacology: A Translational Evidence Framework for Peptide Systems in Pancreatic Ductal Adenocarcinoma

Ahmet Akif Kızılkurtlu, Fatih Çiftçi, Özgür Yılmaz
article en

Abstract

In pancreatic ductal adenocarcinoma (PDAC), the problem is access, not merely affinity. Yet recent reviews emphasize discovery platforms, theranostic probes or clinical translation; to our knowledge, none appraises, across peptide roles, what the evidence shows about access, exposure and benefit by disease stage, including negative randomized results. This structured critical review introduces a spatial-pharmacology framework that asks of every peptide what job it performs (drug, targeting or penetration ligand, trigger, antigen or reporter), where it must act, which clinical state can reveal benefit, and which unresolved experiment most threatens translation. By classifying evidence maturity (tiers T0–T5) separately from outcome direction and profiling five translational domains, it compares heterogeneous systems without pooling and prevents evidence transfer between roles. We searched PubMed/MEDLINE, ClinicalTrials.gov, publisher records and citation chains through 13 August 2026 and purposively charted decision-informative programs in a source-linked atlas. Three cross-system conclusions emerge. First, early human evidence differs in kind by role (for example, target access for reporters, immunogenicity for vaccines) and is not interchangeable, while many direct, stromal and immune-enabling peptides remain preclinical. Second, evidence maturity and benefit often diverge: randomized evidence is limited, partly conference- or developer-reported, and largely negative or non-confirmatory, whereas supportive signals come mostly from lower evidence tiers. Third, the decisive missing evidence is role-specific: site-of-action exposure for direct, stromal and penetration peptides, setting-appropriate endpoints for vaccines, and effect on clinical decisions for reporters. We propose six minimum development standards; the framework is a planning heuristic, not a validated predictor of benefit.

PharmaceuticalsVol. 19(11)
TÜBİTAK Marmara Research Center (TR), Fatih Sultan Mehmet Waqf University (TR), Atlas Üniversitesi (TR), Istanbul University (TR)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon